Latest news
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? - Yahoo FinanceYahoo Finance · Sat, 08 Aug 2026 05:12:00 GMTFDA panel to review Grail's blood-based cancer test - FirstWord PHARMAFirstWord PHARMA · Fri, 07 Aug 2026 21:32:11 GMTFDA panel’s peptide vote raises alarms among Phoenix-area health experts - AZ FamilyAZ Family · Fri, 07 Aug 2026 03:43:00 GMTAre peptide injections safe? What doctors say after FDA panel vote - WCAXWCAX · Fri, 07 Aug 2026 03:42:00 GMTWhy Replimune (REPL) Is Up 15.5% After Supportive FDA Panel Vote On IGNYTE Melanoma Data - webull.comwebull.com · Mon, 03 Aug 2026 10:48:22 GMTStockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 03 Aug 2026 00:49:26 GMTWhy Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next - Yahoo FinanceYahoo Finance · Sun, 02 Aug 2026 04:14:00 GMTReplimune (REPL) Rallies After FDA Panel Vote, But Valuation Rem - GuruFocusGuruFocus · Sat, 01 Aug 2026 00:33:45 GMT